Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Sep. 06, 2024 8:39 AM ET By: Dulan Lokuwithana , SA News Editor [Seeking Alpha]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Seeking Alpha
Commenting on the group's valuation, JPM said that the sector has bounced back from 2021–2023 lows to trade at historical levels, with fundamentals improving due to more stable generic pricing and resolution to legal issues (opioid-related). However, analyst Chris Schott added, “While there is renewed Street interest/excitement in new launches across the specialty group (both branded as well as complex generic/biosimilars), we believe investors need to remain selective on these opportunities.” The Merck ( MRK ) spinoff Organon ( OGN ) indicates an inexpensive valuation on an absolute basis, Schott argued. However, with the stock rallying significantly over the past several months, “we see better risk reward elsewhere in the group,” he added. J.P. Morgan downgraded Organon ( OGN ) to underweight from neutral and called the rating change “largely a relative call within the group,” as it raised the price target to $20 from $18 per share. The firm upgraded Amneal ( AMRX ) to neut
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $55.00 price target on the stock.MarketBeat
- Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceAccesswire
- Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ... [Yahoo! Finance]Yahoo! Finance
- Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024Accesswire
AMPH
Earnings
- 11/6/24 - Beat
AMPH
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- 11/12/24 - Form 4
- AMPH's page on the SEC website